Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE-Reference-Cited by-同舟云学术

Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE

Published:2012-03-14 Issue:7 Volume:13 Page:406-415
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Hodder S¹,Arasteh K²,De Wet J³,Gathe J⁴,Gold J⁵,Kumar P⁶,Mohapi L⁷,Short W⁸,Crauwels H⁹,Vanveggel S⁹,Boven K¹⁰

Affiliation:

1. UMDNJ-New Jersey Medical School; Newark; NJ; USA

2. EPIMED c/o Auguste-Viktoria-Clinic; Berlin; Germany

3. Spectrum Health; Vancouver; British Columbia; Canada

4. Therapeutic Concepts - Donald R. Watkins Foundation; Houston; TX; USA

5. Albion Street Centre; Surry Hills; NSW; Australia

6. Infectious Diseases; Georgetown University Hospital; Washington, DC; USA

7. Perinatal HIV Research Unit; University of the Witwatersrand; Johannesburg; South Africa

8. Division of Infectious Diseases; Jefferson Medical College of Thomas Jefferson University; Philadelphia; PA; USA

9. Tibotec BVBA; Beerse; Belgium

10. Tibotec Inc.; Titusville; NJ; USA

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1468-1293.2012.00991.x/fullpdf

Reference29 articles.

1. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study;Squires;J Antimicrob Chemother,2011

2. da Silva A Cohen D Gibbs S et al Impact of gender on response to lopinavir/ritonavir (LPV/r) tablets dosed QD or BID administered with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in antiretroviral-naïve (ARV) subjects: results from Study M05-730 17th International AIDS Conference 2008

3. Fourie J Flamm J Rodriguez-French A et al ARTEMIS: week 96 safety and efficacy of darunavir/r by gender, age and race 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention 2009

4. Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of gender;Smith;J Acquir Immune Defic Syndr,2007

5. Smith K Tierney C Daar E et al Association of race/ethnicity and sex on outcomes in ACTG Study A5202 18th Conference on Retroviruses and Opportunistic Infections 2011

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV;HIV Medicine;2024-02-20

2. Participation of HIV-1 infected treatment-naive females in clinical trials and sex differences in efficacy and safety outcomes;AIDS;2023-01-06

3. Sex Differences in Non-AIDS Comorbidities Among People With Human Immunodeficiency Virus;Open Forum Infectious Diseases;2021-11-03

4. Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies;Antiviral Therapy;2021-11

5. Women Living with/or Affected by HIV: Frugality and the Politics of Deprivation;Providing HIV Care: Lessons from the Field for Nurses and Healthcare Practitioners;2021